A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan's China Airlines finalizes order for 10 A350-1000s
03/31/2025 10:27 PM - Culture
Filmmaker Midi Z asks the world to help war-torn, quake-hit Myanmar
03/31/2025 10:18 PM - Culture
20,000 Indonesians celebrate Eid al-Fitr in Taipei
03/31/2025 09:40 PM - Sports
All-time CPBL home run leader Ngayaw‧Ake' to retire in September
03/31/2025 09:13 PM - Cross-Strait
2nd Chinese 'military unification' influencer leaves Taiwan
03/31/2025 09:03 PM